How to buy Mereo BioPharma Group stock

Mereo BioPharma Group plc is a biotechnology business based in the US. Mereo BioPharma Group shares (MREO) are listed on the NASDAQ and all prices are listed in US Dollars. Mereo BioPharma Group employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

Mereo BioPharma Group share price

Use our graph to track the performance of MREO stocks over time.

Mereo BioPharma Group shares at a glance

• Key figures

Information last updated 2021-04-19.

52-week range	$1.12 - $4.71
50-day moving average	$3.80
200-day moving average	$3.06
Wall St. target price	$653.21
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.43

Buy Mereo BioPharma Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Mereo BioPharma Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Mereo BioPharma Group plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mereo BioPharma Group financials

Gross profit TTM	$0
Return on assets TTM	-31.43%
Return on equity TTM	-1294.27%
Profit margin	0%
Book value	$2.47
Market capitalisation	$362.6 million

TTM: trailing 12 months

Shorting Mereo BioPharma Group shares

There are currently 8.2 million Mereo BioPharma Group shares held short by investors – that's known as Mereo BioPharma Group's "short interest". This figure is 71.4% up from 4.8 million last month.

There are a few different ways that this level of interest in shorting Mereo BioPharma Group shares can be evaluated.

Mereo BioPharma Group's "short interest ratio" (SIR)

Mereo BioPharma Group's "short interest ratio" (SIR) is the quantity of Mereo BioPharma Group shares currently shorted divided by the average quantity of Mereo BioPharma Group shares traded daily (recently around 2.7 million). Mereo BioPharma Group's SIR currently stands at 3.06. In other words for every 100,000 Mereo BioPharma Group shares traded daily on the market, roughly 3060 shares are currently held short.

However Mereo BioPharma Group's short interest can also be evaluated against the total number of Mereo BioPharma Group shares, or, against the total number of tradable Mereo BioPharma Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mereo BioPharma Group's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Mereo BioPharma Group shares in existence, roughly 80 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Mereo BioPharma Group shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Mereo BioPharma Group.

Find out more about how you can short Mereo BioPharma Group stock.

Mereo BioPharma Group share dividends

We're not expecting Mereo BioPharma Group to pay a dividend over the next 12 months.

Mereo BioPharma Group share price volatility

Over the last 12 months, Mereo BioPharma Group's shares have ranged in value from as little as $1.12 up to $4.711. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group's is 0.7463. This would suggest that Mereo BioPharma Group's shares are less volatile than average (for this exchange).

Mereo BioPharma Group overview

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom. .

Frequently asked questions

What percentage of Mereo BioPharma Group is owned by insiders or institutions?
Currently 0.242% of Mereo BioPharma Group shares are held by insiders and 62.518% by institutions. How many people work for Mereo BioPharma Group?
Latest data suggests 38 work at Mereo BioPharma Group. When does the fiscal year end for Mereo BioPharma Group?
Mereo BioPharma Group's fiscal year ends in December. Where is Mereo BioPharma Group based?
Mereo BioPharma Group's address is: 1 Cavendish Place, London, United Kingdom, W1G 0QF What is Mereo BioPharma Group's ISIN number?
Mereo BioPharma Group's international securities identification number is: US5894921072 What is Mereo BioPharma Group's CUSIP number?
Mereo BioPharma Group's Committee on Uniform Securities Identification Procedures number is: 589492107